Chemicals

Amyris to acquire Oobli to broaden sweet protein platform

Imani NdlovuNovember 16, 20265 min read0 views

At a glance

  • The proposed acquisition would pair Amyris’s fermentation manufacturing capacity with Oobli’s sweet protein technology and commercial portfolio.
  • Amyris plans to acquire Oobli, adding fermentation-derived sweet proteins to its biomanufacturing platform. The companies expect the transaction to close in the coming weeks, with Oobli’s customer commitments continuing uninterrupted.
A wide editorial illustration shows stainless-steel fermentation tanks, a glass bioreactor and a protein ribbon model beside fresh berries in a clean laboratory setting.

Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, Calif., announced plans to acquire Oobli Inc., a Davis, Calif.-based sweet protein innovator. Oobli produces fermentation-based sweet protein ingredients designed to help food and beverage brands reduce sugar without sacrificing taste.

The transaction would combine Amyris’s scientific capabilities and manufacturing depth with Oobli’s protein fermentation expertise. Amyris said the acquisition represents a strategic commercial and technology expansion, accelerating its presence in protein- and peptide-based solutions across end markets.

The deal follows Amyris’s manufacturing capacity expansion earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. According to Amyris, Oobli’s commercial portfolio of sweet proteins will be the first to benefit from the combined platform.

Oobli has spent the past decade refining a fermentation process to produce sweet proteins naturally found in rare fruits and berries near the equator. The company says its sweet proteins are the first of their kind in the sugar-reduction category. They are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, according to Oobli.

Oobli says the ingredients deliver sweetness without gut disruption or blood sugar spikes. Its portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, scientifically known as brazzein, monellin and thaumatin, respectively. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor.

Oobli is targeting a broad range of categories, from sports nutrition and dairy to beverages, chocolate, bakery and confectionery. The company links the opportunity to growing consumer awareness of metabolic health and the benefits of reducing sugar.

Kathy Fortmann, Amyris’s chief executive officer, said Oobli offers a commercial and technology platform that complements Amyris’s own. She said combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden opportunities in food and beverage, personal care, flavor and fragrance, agriculture and beyond.

Ali Wing, Oobli’s chief executive officer, said joining Amyris would provide the scale and resources to pursue the company’s ambition of making sweet proteins a global standard in sweetness solutions. Fortmann said biomanufactured solutions win when they align with consumer demand and market needs, adding that Oobli’s platform addresses sweet taste, sugar reduction and clean label at the same time.

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships would continue to be honored without interruption as Oobli’s portfolio expands within the company.

Reported by Imani Ndlovu, Industrial Water Treatment Chemicals Editor.